Marshall Wace LLP Sells 96,624 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Marshall Wace LLP lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 70.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 41,382 shares of the company's stock after selling 96,624 shares during the period. Marshall Wace LLP owned 0.08% of Enliven Therapeutics worth $931,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Barclays PLC grew its stake in shares of Enliven Therapeutics by 295.8% in the third quarter. Barclays PLC now owns 56,217 shares of the company's stock worth $1,435,000 after purchasing an additional 42,012 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Enliven Therapeutics in the 3rd quarter worth approximately $559,000. Lord Abbett & CO. LLC purchased a new position in shares of Enliven Therapeutics during the third quarter valued at approximately $8,199,000. SG Americas Securities LLC raised its holdings in shares of Enliven Therapeutics by 66.1% during the fourth quarter. SG Americas Securities LLC now owns 16,629 shares of the company's stock valued at $374,000 after acquiring an additional 6,616 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock worth $233,000 after acquiring an additional 1,275 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Trading Up 0.0 %

Enliven Therapeutics stock traded up $0.01 on Monday, hitting $20.52. 87,476 shares of the stock traded hands, compared to its average volume of 259,880. The business's fifty day simple moving average is $19.17 and its 200 day simple moving average is $22.34. The firm has a market cap of $1.01 billion, a P/E ratio of -10.78 and a beta of 1.07. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the sale, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. This represents a 1.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the completion of the transaction, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at $265,330. This trade represents a 20.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,751 shares of company stock worth $1,331,288 in the last 90 days. Insiders own 29.20% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright upped their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 21st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.